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case report
Maternally-inherited diabetes 
with deafness (MIDD) and 
hyporeninemic hypoaldosteronism
Diabetes mitocondrial (MIDD) e hipoaldosteronismo hiporreninêmico
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SUMMARY
Maternally-inherited diabetes with deafness (MIDD) is a rare form of monogenic diabetes 
that results, in most cases, from an A-to-G transition at position 3243 of mitochondrial DNA 
(m.3243A>G) in the mitochondrial-encoded tRNA leucine (UUA/G) gene. As the name suggests, 
this condition is characterized by maternally-inherited diabetes and bilateral neurosensory 
hearing impairment. A characteristic of mitochondrial cytopathies is the progressive multisys-
temic involvement with the development of more symptoms during the course of the disease. 
We report here the case of a patient with MIDD who developed hyporeninemic hypoaldosteron-
ism. Arq Bras Endocrinol Metab. 2012;56(8):574-7
SUMÁRIO
O diabetes mitocondrial (MIDD) é uma forma rara de diabetes monogênico resultante, na maio-
ria dos casos, da mutação mitocondrial A3243G. Essa condição é caracterizada por diabetes de 
transmissão materna e disacusia neurossensorial. Uma característica das mitocondriopatias é 
o envolvimento progressivo de outros órgãos ou sistemas, levando ao aparecimento de diver-
sos sintomas durante o curso da doença. Este relato descreve o caso de um paciente com MIDD 
que, durante o período de acompanhamento, apresentou hipoaldosteronismo hiporreninêmi-
co. Arq Bras Endocrinol Metab. 2012;56(8):574-7
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INTRODUCTION
Maternally inherited diabetes and deafness (MIDD) (OMIM # 520000) is a rare form of diabetes 
that results, in most cases, from an A-to-G transition at 
position 3243 of mitochondrial DNA (m.3243A>G) in 
the mitochondrial-encoded tRNA leucine (UUA/G) 
gene. Besides this point mutation, there are other less 
frequent variants also associated with MIDD (1).
MIDD is characterized, as the name suggests, by 
maternally-inherited diabetes and bilateral neurosen-
sory hearing impairment. Although the age of diabetes 
onset is variable, many patients are young. Guillausseau 
and cols., in a multicenter study, found a mean age at 
diagnosis of diabetes of 38.8 ± 9.6 years, ranging from 
12 to 67 years, and that the presentation is either type 1 
or type 2 diabetes (2). In type 2-like phenotype the pa-
tients can initially be treated with diet or sulphonylurea, 
but they may develop insulin dependency (3,4). Impair-
ment of insulin secretory capacity was demonstrated in 
individuals carrying the m.3243A>G mutation, possi-
bly the primary defect contributing to the development 
of diabetes mellitus (5-7). The molecular mechanisms 
responsible for the development of this insulin-requir-
ing diabetes are complex and seem to be related to 
beta-cells dysfunction, loss of beta-cells mass (8,9), and 
insulin deficiency (3,5-7,9). Possibly, the early primary 
defect in individuals carrying the m.3243A>G muta-
tion is the impairment of insulin secretory capacity due 
to the progressive reduction in o xidative phosphory-
lation involving the glucose-sensing mechanism of 
beta-cells (6). The preferential replication of mtDNA 
molecules carrying the 3243 mutation over wild-type 
molecules may also be involved in the progressive loss 
of insulin secretion (3,10).
 A characteristic of mitochondrial cytopathies is 
the progressive multisystemic involvement, with the 
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deve lopment of more symptoms during the course of 
the disease. Besides diabetes mellitus and deafness, the 
main features of MIDD, other organs may be involved. 
Metabolically active organs, such as muscle, retina, 
myocardium, cochlea, kidney, and brain are frequently 
affected. Myopathy is manifested as painful muscle 
weakness affecting the lower limbs. Muscular disorders 
were observed in 43% of MIDD patients (2). Macular 
retinal dystrophy is the most common ophthalmic 
abnormality, observed in 86% of patients with MIDD 
(11). This condition includes pigmented lesions in the 
retina, and atrophy of the choroid or retinal epithelium, 
a “salt and pepper” pigmentary retinopathy, generally 
without consequences on visual acuity (1). Patients with 
MIDD also have considerable risk for cardiac disorders. 
Left ventricular hypertrophy, Wolff-Parkinson-White 
syndrome and other cardiac conduction abnormalities, 
as well as heart failure have been reported in these 
patients (1,12-14). In addition to diabetes, short 
stature is the most common endocrine manifestation 
of MIDD, and a deficiency in the release of growth 
hormone has been reported (15). 
Coenzyme Q10 (CoQ10) plays a central role in the 
mitochondrial respiratory chain. It acts as an electron 
carrier, supporting adenosine triphosphate (ATP) syn-
thesis in the inner mitochondrial membrane. In addition, 
CoQ10 has also antioxidant and membrane-stabilizing 
properties. Previous reports showed beneficial effects of 
CoQ10 on some neuromuscular symptoms, prevention 
of progressive insulin secretory defect, exercise intoler-
ance, hearing loss, myocardial dysfunction, and intesti-
nal pseudo-obstruction in MIDD patients (13,16-19).
The m.3243 A>G mutation causes an alteration of 
the tertiary structure of the tRNA Leu leading to ab-
normal dimerization of the molecule. Defects in mi-
tochondrial protein synthesis and respiratory activity 
were observed in cybrid cells from patients carrying 
the m.3243A>G mutation (20). This mutation has also 
been associated with other cellular biochemical dys-
functions such as increased oxidative stress, impaired 
calcium homeostasis, reduced mitochondrial mem-
brane potential, and increased apoptosis (1,21).
We report here the case of a patient with MIDD 
who developed hyporeninemic hypoaldosteronism.
CASE REPORT 
A 50-year-old man was diagnosed with diabetes mellitus 
at the age 19, and has been treated with insulin since 
then. Diabetes was diagnosed based on the history of 
thirst, polyuria, and body weight loss. Bilateral neuro-
sensory hearing loss was diagnosed at the age of 28, and 
required the use of a hearing aid. The patient’s height 
and weight were 157 cm and 47 kg, respectively, with a 
body mass index of 19.1 kg/m2. Family history showed 
hearing loss in two sisters. The patient’s mother was 
never diagnosed with diabetes or hearing impairment 
during her life; she died at the age of 78. 
Based on the findings of diabetes mellitus, hearing 
impairment and short stature, the patient was suspec-
ted to have MIDD. Molecular genetic analysis was then 
performed in the patient (proband) and available rela-
tives. The presence of an A-to-G transition at nucleo-
tide pair 3243 of the mitochondrial gene was identi-
fied in the proband, his two sisters, two nieces, and 
his mother, confirming the MIDD diagnosis. Glucose 
tolerance test was performed in his mother, sisters, and 
nieces, with normal glucose tolerance levels (Figure 1). 
He was started on Coenzyme Q10, 150 mg daily. Os-
teoporosis was also diagnosed, and alendronate 70 mg 
weekly was prescribed.
In recent years, the patient’s HbA1c levels have 
ranged from 7.1% to 8.4%. Serum creatinine (0.56 to 
0.79 mg/dL) and albuminuria (4.6 to 7.0 ug/min in 12-
hour specimen) were normal. Glomerular filtration rate 
was 78 mL/ min/1.73 m2. Ophthalmological examina-
tion revealed ocular fundus without diabetic retinopathy.
During routine electrolyte measurements, persis-
tent hyperkalaemia was noted with serum potassium 
concentrations ranging from 5.0 to 6.4 mmol/L, and 
serum sodium ranging from 134 to 139 mmol/L. Fur-
ther investigation showed 24-h urinary potassium of 46 
Figure 1. Pedigree of the studied family with the mitochondrial A3243G 
mutation. Mutation with diabetes ( ), mutation with normal glucose 
tolerance ( ), wild gene ( ), untested ( ). D: indicates neurosensory 
deafness; N: normal audiometric test.
MIDD and hyporeninemic hypoaldosteronism
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mEq, urinary sodium of 362 mEq, venous pH of 7.32, 
pCO2 of 53 mmHg, and base excess of 0 mmol/L. The 
patient was not taking any medication other than in-
sulin, coenzyme Q10, and alendronate. Evaluation of 
his renin-angiotensin-aldosterone system showed un-
detectable basal plasma renin activity (< 0.4 ng/mL/h; 
reference: 0.4-0.7 ng/mL/h) and serum aldosterone 
(basal: < 2.0 ng/dL; post-ACTH: < 2.0 ng/dL; refer-
ence: 2.0-16.0 ng/dL). 
Morning basal and ACTH-stimulated cortisol levels 
were 15.9 ug/dL (reference: 5.4-25 ug/dL) and 27.5 
ug/dL (reference: > 20 ug/dL), respectively. These 
laboratory findings pointed toward hyporeninemic hy-
poaldosteronism. Accordingly, replacement mineralo-
corticoid therapy with fludrocortisone (0.2 mg PO dai-
ly) was instituted; one month later, he reported clinical 
improvement with increased strength and sense of well-
being; his serum potassium decreased to 5.0 mmol/L, 
and serum sodium increased to 141 mmol/L. 
Molecular analysis of the A3243G mutation
Total DNA was extracted from peripheral blood leuko-
cytes using a commercial kit (Puregene DNA Isolation 
Kit, Gentra System, Minneapolis, MN, USA). Detec-
tion of the 3243 A-to-G transition in the mitochondrial 
tRNA Leu (UUR) gene was carried out by polymerase 
chain reaction A3243G (PCR), Apa I digestion, and 
acrylamide gel electrophoresis. Bands were visualized 
by ethidium bromide staining.
DISCUSSION
In this paper, we present the case of a male patient with 
MIDD due to an A-to-G transition at position 3243 in 
the mitochondrial-encoded tRNA leucine (UUA/G) 
gene. The patient also developed hyporeninemic hy-
poaldosteronism.
Hyperkalemia occurs in diabetic patients at higher 
percentages than in the general population. Jarman 
and Mather found serum potassium > 5.0 mmol/L in 
15% patients attending a diabetic clinic (22). The major 
causes of hyperkalemia are advanced renal failure, heart 
failure resulting in renal hypoperfusion, or hypoaldo-
steronism. Among the causes of hypoaldosteronism, 
the use of drugs that interfere with the release or action 
of aldosterone, such as non-steroidal antiinflamma-
tory drugs, angiotensin-converting enzyme inhibitors 
and/or angiotensin II-receptor blockers, heparin, tri-
methoprim, and potassium-sparing diuretics, should all 
be considered. Other less frequent causes are primary 
adrenal insufficiency and hyporeninemic hypoaldoste-
ronism syndrome (HHS). 
Renin is produced by the juxtaglomerular cells of 
the kidney that are spread throughout the renal cortex. 
Impaired renal secretion of renin causes a deficiency in 
aldosterone secretion, i.e., hyporeninemic hypoaldo-
steronism. This disorder results in chronic natriuresis 
secondary to sodium loss in the distal nephron, with 
consequent decrease in potassium and hydrogen secre-
tion. Retention of these ions leads to hyperkalemia and 
mild hyperchloremic metabolic acidosis (23,24). 
Reduced secretion of renin in diabetic patients may 
be due to several causes: small vessel kidney disease, 
production of an inactive form of renin, inadequate 
sympathetic stimulation of renin-producing cells by au-
tonomic neuropathy, and a physiological suppression of 
renin release by volume overload (25-27).
Mitochondrial gene mutations underlie a number of 
disorders. Several tissues become functionally defective 
when the amount of mutant DNA exceeds a certain 
threshold, which depends on the mutation and the ex-
tent to which the cell relies on mitochondrial function. 
The presentation of mt A>G 3243 mutation is variable, 
ranging from mild to severe phenotypes. 
 The patient described here, besides mitochondrial 
diabetes, presented clinically manifested hyporeninemic 
hypoaldosteronism during the follow-up. Given that he 
was not taking any drug that could potentially interfere 
with the release or action of aldosterone and had no 
features of renal failure, the presence of hyperkalemia 
may be attributed to hyporeninemic hypoaldosteron-
ism. Furthermore, because hyperglycemia induces the 
release of potassium from the intra- to the extracellular 
compartment, it contributes to the worsening of hyper-
kalemia (28). In fact, in this patient, hyperkalemia was 
aggravated whenever his blood glucose concentration 
rose (data not shown). Fludrocortisone was given to 
the patient, and hyperkalemia was promptly corrected.
Shimizu and cols. have previously described three 
familial cases of mitochondrial diabetes with hyperkale-
mia (29). Mild acidosis was detected and plasma renin 
and aldosterone concentrations were low. Histopath-
ological examination of the kidney revealed tubulo-
interstitial changes and minor glomerular abnormali-
ties, whereas electron microscopy depicted numerous 
abnormal mitochondria in the epithelium of both the 
glomeruli and the tubules. The authors inferred that 
mitochondrial damage may be more severe in the jux-
MIDD and hyporeninemic hypoaldosteronism
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taglomerular cells than in other kidney cells, leading to 
hyporeninemic hypoaldosteronism. A similar consider-
ation may be appropriate for our patient.
In summary, the presence of hyperkalemia in pa-
tients with MIDD should alert the physician to look for 
the development of hyporeninemic hypoaldosteronism.
Disclosure: no potential conflict of interest relevant to this article 
was reported.
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